skip to main content
Home
About Us
Leadership & Advisors
Events & Media
Contact Us
Products
Transplant
VitaGraft Liver
VitaGraft Kidney
Oncology
DetermaIO
DetermaCNI
Publications
Biopharma Services
Investors
Oncocyte Company Profile
Stock Information
Events & Presentations
SEC Filings
Analyst Coverage
News Releases
Corporate Governance
Information Request
Contact Us
Go to...
Home
About Us
Leadership & Advisors
Events & Media
Contact Us
Products
Transplant
VitaGraft Liver
VitaGraft Kidney
Oncology
DetermaIO
DetermaCNI
Publications
Biopharma Services
Investor
Oncocyte Company Profile
Stock Information
Events & Presentations
SEC Filings
Analyst Coverage
News Releases
Corporate Governance
Board of Directors
Committees
Governance Documents
Board Diversity Matrix
Information Request
Contact Us
Email Alerts
Contact Us
.
Investment
Highlights
Investor
Investment Highlights
Pipeline positioned to capitalize on standard of care moving to liquid biopsy
Early diagnosis focused on the largest market segment with the greatest unmet needs
Clinical data demonstrates strong assay performance
Compelling value proposition for healthcare providers, patients, and payers
Strong leadership with commercialization experience
Stock Information
More +
Events & Presentation
No upcoming events scheduled at this time.
Investor Presentation
More +
Latest News
Oncocyte Appoints Andrea James as Chief Financial Officer
Read More >
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
Read More >
More +
Corporate Governance
Financial & Filings
Contact IR
